All Stories

  1. Empirical caspofungin therapy in clinical practice for suspected invasive fungal disease in adults with acute lymphoblastic leukaemia
  2. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
  3. Aspergillus PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities
  4. Tumorinduzierte Hyperkalzämie
  5. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
  6. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies
  7. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples
  8. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation—guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
  9. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals
  10. Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
  11. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program
  12. Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation
  13. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology
  14. Pulmonale Komplikationen nach hämatopoetischer Stammzelltransplantation – eine Herausforderung für die Intensivpflege
  15. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole
  16. Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study
  17. Differential Requirement for a Cellular Type-1 Immune Response in Tumor-Associated Versus Alloantigen-Targeted GvT Effects
  18. Long-term follow-up of peripheral blood stem cell transplantation from mismatched related and unrelated donors
  19. Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
  20. Management of sepsis in neutropenia: guidelines of the infectious diseases working party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
  21. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study
  22. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
  23. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
  24. Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in Adult Patients With Acute Lymphoblastic Leukemia: No Difference in Related Compared With Unrelated Transplant in First Complete Remission
  25. Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma
  26. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis
  27. Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies
  28. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)
  29. Synergistic growth inhibitory effects of interferon-α and lovastatin on bcr-abl positive leukemic cells
  30. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients
  31. Sepsis in neutropenia
  32. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia
  33. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor
  34. 192Dose-reduced conditioning with fludarabine/melphalan followed by allogeneic stem cell transplantation for patients with advanced stage II/III multiple myeloma
  35. 50 Outcomes of HLA identical siblings are comparable to unrelated hematopoietic stem cell transplantation (HSCT) in adults with acute myeloid leukemia
  36. Erythropoietic recovery during treatment with Darbepoietin-alpha after impaired rHuEPO response to anemia in two patients with osteomyelofibrosis after peripheral blood stem cell transplantation
  37. Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage
  38. TBI-Based Reduced Intensity Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) in Patients with High-Risk Hematologic Malignancies
  39. Nonmyeloablative Conditioning Regimen in Patients with High Risk Acute Myeloid Leukemia: Unrelated and Sibling Allogeneic Hematopoietic Stem Cell Transplantation
  40. Mycophenolate mofetil for the prophylaxis of acute graft-versus-host disease in stem cell transplant recipients
  41. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience
  42. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT)
  43. FACTOR XIII REPLACEMENT IN STEM CELL TRANSPLANT (SCT) RECIPIENTS WITH SEVERE GRAFT-VERSUS-HOST DISEASE OF THE BOWEL: REPORT OF AN INITIAL EXPERIENCE
  44. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis
  45. Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients
  46. New immunosuppressants in BMT/GVHD
  47. New therapeutic modalities in the treatment of graft-versus-host disease
  48. Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience
  49. Eosinophilia in bone marrow after hematopoetic stem cell transplantation: does it indicate the onset of acute graft-versus-host disease?
  50. Allogeneic hematopoietic stem cell transplantation in patients with beta-thalassemia
  51. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab
  52. Successful treatment of thrombocytopenia and hemolytic anemia with IvIG in a patient with lupus-like syndrome after mismatched related PBSCT
  53. 'Graft versus host�-Reaktion - Stellenwert neuer Immunsuppressiva
  54. Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study
  55. Toxoplasmosis, a Severe Complication in Allogeneic Hematopoietic Stem Cell Transplantation: Successful Treatment Strategies during a 5-Year Single-Center Experience
  56. Epidemiology and interventional treatment strategies of infectious complications after allogenic stem-cell transplantation
  57. Preface
  58. New strategies in GVHD prophylaxis
  59. New strategies in the treatment of graft-versus-host disease
  60. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study
  61. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients
  62. Mycophenolate mofetil in the prevention of rejection after kidney transplantation
  63. Atypical Chronic Myeloid Leukaemia with Trisomy 21 Mosaicism as a Sole Chromosomal Abnormality
  64. Mycophenolate Mofetil for the Treatment of Acute and Chronic GVHD in Bone Marrow Transplant Patients
  65. Treatment of documented deep fungal infections in patients with sibling or unrelated stem cell transplantation: a study comparing safety and efficacy of conventional amphotericin B to liposomal amphotericin B (ambisome®)
  66. PLASMA LEVELS OF MYCOPHENOLIC ACID AFTER ORAL MYCOFENOLAT MOFETIL IN PATIENTS AT HIGH RISK FOR GRAFT VERSUS HOST DISEASE (GVHD) AFTER BONE MARROW TRANSPLANTATION
  67. MPA/MPAG LEVELS DURING IV MYCOPHENOLATE MOFETIL (CELLCEPT®) PROPHYLAXIS FOR ACUTE GVHD IN BMT/SCT RECIPIENTS.
  68. Tyrosine phosphorylation in peripheral T cells of kidney transplant recipients: analyses of baseline levels and response to T cell receptor stimulation.
  69. NON INVASIVE VENTILATORY SUPPORT (CPAP) IN BMT/PBSCT
  70. Lovastatin induces p21WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition.
  71. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient
  72. Inflammatory mediators in bronchoalveolar lavage fluid and plasma in leukocytopenic patients with septic shock-induced acute respiratory distress syndrome
  73. Effects of NG-Nitro-L-Arginine-Methyl-Ester on Cardiopulmonary Function and Biosynthesis of Cyclooxygenase Products
  74. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis.
  75. Alterations of Protein Tyrosine Phosphorylation in T Cells of Immunocompromised Patients
  76. The Optimum Use of Intravenous Immunoglobulin for Prophylaxis of Opportunistic Infection in HIV-Infected Adults
  77. INFLAMMATORY MEDIATORS IN BRONCHOALVEOLAR LAVAGE FLUID AND PLASMA IN LEUKOCYTOPENIC PATIENTS WITH SEPTIC SHOCK INDUCED ARDS
  78. EFFICACY OF MECHANICAL VENTILATION FOR SEVERE RESPIRATORY FAILURE IN BONE MARROW TRANSPLANT PATIENTS
  79. Inflammatory Mediators in BAL Fluid as Markers of Evolving Pneumonia in Leukocytopenic Patients
  80. Reciprocal Changes in Circulating Interleukin‐6 and Its Soluble Receptor during Evolving Sepsis in Leukocytopenic Patients
  81. Nitric oxide synthase inhibition by L-NAME in leukocytopenic patients with severe septic shock
  82. Efficacy and kinetics of bone marrow processing and enrichment of haematopoietic progenitor cells (HPC) by a large-volume apheresis procedure
  83. Volume-Controlled Versus Biphasic Positive Airway Pressure
  84. Mediators in Sepsis and Septic Shock
  85. A Controlled Trial of Intravenous Immune Globulin for the Prevention of Serious Infections in Adults With Advanced Human Immunodeficiency Virus Infection
  86. A controlled trial of intravenous immune globulin for the prevention of serious infections in adults with advanced human immunodeficiency virus infection
  87. Characterization of Autoantibodies to Natural Killer Cells in HIV‐Infected Patients
  88. Volume-controlled versus biphasic positive airway pressure ventilation in leukopenic patients with severe respiratory failure
  89. Bronchiolitis obliterans mit organisierender Pneumonie: Differentialdiagnose der antibiotikarefraktären Pneumonien